Prospective Study of the Association between different lipid parameters and MACEs within very high-risk ASCVD patients

The study of the Association between different lipid parameters and MACEs within very high-risk ASCVD patients

Status

Recruiting

Phases

Phase 4

Study type

Interventional

Source

ChiCTR

Registry ID

ChiCTR2500114167

Enrollment

Unknown

Registered

2025-12-08

Start date

2023-11-07

Completion date

Unknown

Last updated

2025-12-15

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Atherosclerotic cardiovascular disease

Interventions

Test group:Combination therapy of oral lipid-lowering drugs and PCSK9 inhibitor Elomumab injection for treatment

Control group:Oral lipid-lowering drugs

Eligibility

Sex/Gender

All

Age

18 Years to 80 Years

Inclusion criteria

Inclusion criteria: (1) Age =2 additional high-risk conditions; (2) Baseline LDL-C >4.14 mmol/L (>160 mg/dL).

Exclusion criteria

Exclusion criteria: (1) severe comorbidities limiting life expectancy including: advanced cardiac dysfunction (left ventricular ejection fraction [LVEF] <20%);stage 4-5 chronic kidney disease (estimated glomerular filtration rate <30 mL/min/1.73 m²); severe hepatic impairment; (2) comorbidities potentially confounding outcomes: dementia, active malignancy, solid organ transplant recipients.

Design outcomes

Primary

Measure	Time frame
Low-density lipoprotein cholesterol;	—

Secondary

Measure	Time frame
total cholesterol;high-density lipoprotein cholesterol (non-HDLC);non-high-density lipoprotein cholesterol (non-HDLC);Lipoprotein(a);	—

Countries

China

Contacts

Public ContactHandong Zhu

Wuhan Asia Heart Hospital

Harryzhuhandong@outlook.com+86 189 6398 0166

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026